Indication
Recurrent Thyroid Cancer
2 clinical trials
2 products
1 drug
Clinical trial
Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid CancerStatus: Recruiting, Estimated PCD: 2027-12-01
Clinical trial
A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination With Paclitaxel in Patients With Advanced Anaplastic Thyroid CancerStatus: Completed, Estimated PCD: 2019-02-27
Product
efatutazoneDrug
paclitaxel